Respadd, in collaboration with Ofma and the Ceip-Addictovigilance Association, has just published a new guide "Opioid painkillers: what you need to know what to do". "An unlimited prescription for analgesics in the United States in the 1990s ended with the Purdue Pharma campaign to sell OxyContin, in conjunction with heroin rebirth, in particular black tar, 20 years later, over 70,000 deaths due to one year of overdose, one in 4500 people This tragedy has caused forensic medicine to send letters to doctors prescribing medicines, informing them that statistically one of their patients who had previously prescribed opioids died in the previous year of drug overdose, "recalls Anne Borgne, president of Respadd, in her introduction to the guide. "This health crisis is an example of the importance of the independence of carers from the pharmaceutical industry and the need to address individual health determinants by strengthening the health skills and knowledge of both the patient and those around him". all health professionals, "he explains." Action in health promotion, a prerequisite for promoting virtuous health behaviors, early intervention in emergency situations, promoting autonomy and enabling all informed choices based on evidence. This is a challenge related to the new Respadd publication, offering specialists the information they need for the good use of opioid analgesics, in an easy-to-obtain format, highlighting the knowledge and actions flowing from it. "For his part, Professor Nicolas Authier, director of the French Pain Relief Observatory, in his preface in this book, he mentions that "opioid painkillers are consumed by about 12 million French people each year." "Although exposure to this class of drugs has been relatively stable for over ten years, the evolution of hospitalization for the use of opioid narcotics and deaths. it is much larger in France, "notes the doctor, and notes that the number of Frenchmen treated with strong opioid analgesics (morphine, fentanyl or oxycodone) has almost doubled in the last decade, mainly due to non-cancer pain (…) It is the role of every health actor to participate in their proper use and inform the French pharmacovigilance system (…) about complications associated with these drugs, the most serious of which is addiction or overdose ", hence the issuance of this guide attaches importance to provide healthcare professionals with the necessary information about these medicines for prescribing and accompanying advice on good practice. "